Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextriferron is an intravenous iron replacement therapy consisting of a complex of ferric hydroxide with partially hydrolyzed dextrin. It is primarily indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. In the context of acute upper gastrointestinal bleeding, it is used to accelerate hemoglobin recovery and improve quality of life by replenishing iron stores more rapidly than oral supplementation. The iron is released from the complex and utilized by the bone marrow for erythropoiesis. Clinical evaluations, such as those conducted at Aarhus Sygehus, have compared its efficacy against oral iron and no supplementation in patients treated endoscopically for gastrointestinal hemorrhage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextriferron.